10 Einträge von 415 mit asia reducing
www.cslbehring.ch
Datum der Indexierung 13.09.2023 07:42:33
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | more quality | health investigator | initiated application |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | more quality | health investigator | initiated application |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 27.03.2023 01:09:20
erkannte Namen Justus Liebig | Ludwig Maximilian | Maximilian University | Marthe DO | Daniel Ricklin | Arthur Liesz | Allison Pettit | Kirsten Coupland | Georgina Clark | Daniel Rader |
weitere Namen in www.cslbehring.ch 10
Subdomain:
extern (outbound) Link/Domain 6 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL recognizes researchers
Kombination Keywords research webinar | university that | behring professor | more prof | learn switzerland | global from | patients products | initiative news | acceleration health | disease with |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Asia Pacific Australia China Japan Korea Singapore Taiwan Middle East Saudi Arabia United Arab Emirates (MEA) Europe Austria Belgium and Luxembourg Czech Republic Denmark Finland France Germany Greece Hungary Italy Netherlands Norway Poland Slovakia reducing triglycerides (a type of fat) in the blood. Patients with very high triglycerides can develop severe and sometimes life-threatening pancreatitis. Dr D’Ombrain said that the RAI recipients’ research addresses important unm
Text Inhalt Text aus URL
Log Metriken 1212067
erkannte Namen Justus Liebig | Ludwig Maximilian | Maximilian University | Marthe DO | Daniel Ricklin | Arthur Liesz | Allison Pettit | Kirsten Coupland | Georgina Clark | Daniel Rader |
weitere Namen in www.cslbehring.ch 10
Subdomain:
extern (outbound) Link/Domain 6 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL recognizes researchers
Kombination Keywords research webinar | university that | behring professor | more prof | learn switzerland | global from | patients products | initiative news | acceleration health | disease with |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Asia Pacific Australia China Japan Korea Singapore Taiwan Middle East Saudi Arabia United Arab Emirates (MEA) Europe Austria Belgium and Luxembourg Czech Republic Denmark Finland France Germany Greece Hungary Italy Netherlands Norway Poland Slovakia reducing triglycerides (a type of fat) in the blood. Patients with very high triglycerides can develop severe and sometimes life-threatening pancreatitis. Dr D’Ombrain said that the RAI recipients’ research addresses important unm
Text Inhalt Text aus URL
Log Metriken 1212067
www.cslbehring.ch
Datum der Indexierung 04.04.2023 15:04:06
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | more quality | initiated application | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | more quality | initiated application | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 11.05.2023 05:27:06
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | more quality | initiated application | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | more quality | initiated application | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 20.06.2023 06:57:52
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords with scientific | behring including | studies learn | that diseases | disease research | products your | clinical patients | more quality | initiated application | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords with scientific | behring including | studies learn | that diseases | disease research | products your | clinical patients | more quality | initiated application | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 21.04.2023 13:38:51
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | more quality | initiated application | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | more quality | initiated application | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 02.10.2023 14:46:47
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies diseases | that learn | disease research | products your | clinical patients | more quality | application investigator | health initiated |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies diseases | that learn | disease research | products your | clinical patients | more quality | application investigator | health initiated |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 05.10.2023 09:47:50
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies diseases | that learn | disease research | products your | clinical patients | more quality | application investigator | health initiated |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies diseases | that learn | disease research | products your | clinical patients | more quality | application investigator | health initiated |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 26.10.2023 20:56:34
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies diseases | that learn | disease research | products your | clinical patients | more quality | application initiated | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies diseases | that learn | disease research | products your | clinical patients | more quality | application initiated | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 08.01.2024 08:22:21
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies diseases | that health | disease learn | products research | clinical your | more patients | application quality | initiated investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies diseases | that health | disease learn | products research | clinical your | more patients | application quality | initiated investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
asia, epistaxis and joint bleeds Generate data supporting efficacy & safety, and health economic benefits of high-ratio pdvWF/FVIII vs. 1:1 concentrates Generate data in vWD (including burden of disease), increase awareness of vWD & show benefit of t reducing inhibitor development Clinical studies that increase knowledge of immune tolerance induction with our recombinant Coagulation Factor VIII product Von Willebrand Disease Clinical studies that generate evidence of efficacy
Text Inhalt Text aus URL
Log Metriken 1036330